Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab in pediatric patients: how safe is it?
de Pasquale MD, Castellano A, de Sio L, de Laurentis C, Mastronuzzi A, Serra A, Cozza R, Jenkner A, de Ioris MA. de Pasquale MD, et al. Among authors: jenkner a. Anticancer Res. 2011 Nov;31(11):3953-7. Anticancer Res. 2011. PMID: 22110225
D-CECaT: a breakthrough for patients with neuroblastoma.
Donfrancesco A, Deb G, Angioni A, Maurizio C, Cozza R, Jenkner A, Landolfo A, Boglino C, Helson L. Donfrancesco A, et al. Among authors: jenkner a. Anticancer Drugs. 1993 Jun;4(3):317-21. Anticancer Drugs. 1993. PMID: 8395258 Clinical Trial.
111 renal neoplasms of childhood: a clinicopathologic study.
Jenkner A, Camassei FD, Boldrini R, de Sio L, Ravà L, Bosman C, Boglino C, Donfrancesco A. Jenkner A, et al. J Pediatr Surg. 2001 Oct;36(10):1522-7. doi: 10.1053/jpsu.2001.27036. J Pediatr Surg. 2001. PMID: 11584401
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L, Cozza R, Fidani P, Deb G, De Laurentis C, Inserra A, Dominici C. Donfrancesco A, et al. Among authors: jenkner a. Acta Paediatr Suppl. 2004 May;93(445):6-11. doi: 10.1111/j.1651-2227.2004.tb03048.x. Acta Paediatr Suppl. 2004. PMID: 15176712 Clinical Trial.
Temozolomide in resistant or relapsed pediatric solid tumors.
De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A. De Sio L, et al. Among authors: jenkner a. Pediatr Blood Cancer. 2006 Jul;47(1):30-6. doi: 10.1002/pbc.20516. Pediatr Blood Cancer. 2006. PMID: 16047361 Clinical Trial.
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
Milano GM, Cozza R, Ilari I, De Sio L, Boldrini R, Jenkner A, De Ioris M, Inserra A, Dominici C, Donfrancesco A. Milano GM, et al. Among authors: jenkner a. Cancer. 2006 Apr 15;106(8):1838-45. doi: 10.1002/cncr.21780. Cancer. 2006. PMID: 16532434 Free article. Clinical Trial.
56 results